Information  X 
Enter a valid email address

H. Lundbeck A/S (0I40)

  Print      Mail a friend       Annual reports

Tuesday 14 December, 2010

H. Lundbeck A/S

Lundbeck to establish a strong, dedicated sales...






  * Lundbeck will substantially increase sales and marketing efforts behind
    Lexapro(®) in China
  * Lundbeck already has a foothold in China and stands to benefit from the
    rapidly evolving Chinese CNS market

H. Lundbeck A/S (Lundbeck) announced today a revised agreement with its partner
in China, Xian-Janssen Pharmaceuticals Ltd. (Xian-Janssen), that change the
terms from the current license agreement for Lexapro(®) to a co-promotion
agreement. The new agreement also means that both parties will invest
substantially in more joint sales and marketing efforts for Lexapro(®) in China.

Lundbeck plans to double its current sales organisation in China and the new
joint sales efforts behind Lexapro(®) is to be further expanded in the coming
years. The agreements provide for a highly competitive share of voice in the
Chinese market for anti-depressants.

Lundbeck has had products available in China since 1996 and currently Lexapro(®)
is exclusively promoted by Xian-Janssen. Lundbeck's current sales force of
approximately 50 sales representatives is promoting Ebixa(®) and is also
expected to initiate marketing of Azilect(®) in a couple of years, which is
pending approval.

"With the new agreement with our partner, we get an opportunity to strongly
expand our activities in China and to further strengthen our commercial platform
in this promising region," says Ole Chrintz, Senior Vice President,
International Markets at Lundbeck. "The pharmaceutical market in China, and the
CNS market in particular, is undergoing a rapid development and represents a
substantial commercial opportunity that could contribute meaningfully to
Lundbeck's future."

Though only being the fifth largest market today, China is emerging as one of
the most important markets for growth for the pharmaceutical industry as the
Chinese government is in the midst of expanding the access to healthcare in the
country. The CNS market in China is developing rapidly and is growing faster
than the Chinese pharmaceutical market in general.

By entering a co-promotion agreement, Lundbeck is to increase its value share of
its anti-depressants in China and to significantly increase the share-of-voice
for Lexapro(®) in China. The financial terms of the collaboration are
undisclosed.

The Chinese market for CNS products
In 2009, the Chinese antidepressant market (N6A) had a value of RMB 1.3 billion
(DKK ~1 billion) according to IMS, and has been experiencing more than 20%
annual growth rates in the past years. The most widely used  anti-depressants in
China were by the end of 2009 paroxetine with a value market share of
approximately 18%, sertraline with a share of approximately 10%, fluoxetine with
a share of approximately 10% followed by Cipramil(®) and Lexapro(®) with 6.5%
and 3.0% respectively.

The Alzheimer's disease market in China constituted around RMB 121 million (DKK
~93 million) in 2009 with donepezil having 66% and Ebixa(®) 16% of the value.
The market has been growing by approximately 30% for the last couple of years.

The Chinese market for Parkinson's disease products was RMB 200 million (DKK
~160 million) in 2009.

Xian-Janssen and Lundbeck alliance
In 2002, Lundbeck entered a license agreement for the commercialisation of
Cipramil(®) and Lexapro(® )in China with Xian-Janssen. In 2003 Xian-Janssen
launched Cipramil(®) and in 2006 marketing of Lexapro(®) was initiated.

Financial guidance
The content of this release will have no influence on the Lundbeck Group's
financial guidance for 2010 which was provided on 4 March 2010 in connection
with the release of the financial results for 2009 and further specified with
the release of the third quarter report on 3 November 2010.


Lundbeck contacts

Investors:                           Media:



Palle Holm Olesen                    Mads Kronborg

Chief Specialist, Investor Relations Media Relations Manager

+45 36 43 24 26                      +45 36 43 28 51



Magnus Thorstholm Jensen             Stine Hove Marsling

Investor Relations Officer           External Communication Specialist

+45 36 43 38 16                      +45 36 43 28 33



Jacob Tolstrup

Vice President

+1 847 282 5713



About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical
company highly committed to improving the quality of life for people suffering
from central nervous system (CNS) disorders. For this purpose, Lundbeck is
engaged in the research and development, production, marketing and sale of
pharmaceuticals across the world. The company's products are targeted at
disorders such as depression and anxiety, schizophrenia, insomnia, epilepsy and
Huntington's, Alzheimer's and Parkinson's diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today
Lundbeck employs approximately 5,900 people worldwide. Lundbeck is one of the
world's leading pharmaceutical companies working with CNS disorders. In 2009,
the company's revenue was DKK 13.7 billion (approximately EUR 1.8 billion or USD
2.6 billion). For more information, please visit www.lundbeck.com.





Release no 420: 


http://hugin.info/130085/R/1471980/408610.pdf




This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: H. Lundbeck A/S via Thomson Reuters ONE

[HUG#1471980] 
  



                                                                                                                                                                               

a d v e r t i s e m e n t